Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Lucitanib

Generic Name: Lucitanib

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₂₅N_₃O_₄

CAS Number: 1058137-23-7

Unique Ingredient Identifier: PP449XA4BH

Overview

Lucitanib has been used in trials studying the treatment of ER+, MBC, SCLC, HER2+, and NSCLC, among others.

Background

Lucitanib has been used in trials studying the treatment of ER+, MBC, SCLC, HER2+, and NSCLC, among others.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients

Phase 2

Posted: 2020/02/05

Sponsor:

Haihe Biopharma Co.,...

ID:NCT04254471

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

Phase 1

Withdrawn

Posted: 2019/11/05

Sponsor:Bristol-Myers Squibb

ID:NCT04151563

A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor

Phase 1

Suspended

Posted: 2019/08/01

Sponsor:Clovis Oncology, Inc...

ID:NCT04042116

A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)

Phase 1

Terminated

Posted: 2019/06/20

Sponsor:pharmaand GmbH

ID:NCT03992131

Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810

Phase 1

Posted: 2017/08/24

Sponsor:

Haihe Biopharma Co.,...

ID:NCT03260179

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Promising Pipeline for Mantle Cell Lymphoma Treatment: 22+ Therapies Under Development by 20+ Companies

a month ago

DelveInsight's latest report reveals a robust pipeline with 20+ companies developing 22+ therapies for mantle cell lymphoma, highlighting significant advancement in treatment options for this rare blood cancer.

Groundbreaking T-Cell Therapy Leads to Complete Remission in Stage 4 Breast Cancer Patient

4 months ago

A pioneering clinical trial at the US National Cancer Institute using Tumor Infiltrating Lymphocytes (TIL) therapy successfully eliminated stage 4 breast cancer in patient Judy Perkins, marking a significant breakthrough in immunotherapy.

Mantle Cell Lymphoma Pipeline Shows Promise with Novel Targeted Therapies

8 months ago

The Mantle Cell Lymphoma (MCL) pipeline is robust, featuring over 20 companies developing more than 22 therapies.

FGFR1 Overexpression Identified as a Key Resistance Mechanism to CDK4/6 Inhibitors in ER+ Breast Cancer

6 years ago

A recent study has uncovered that overexpression of FGFR1 in ER+ breast cancer cells can lead to resistance against CDK4/6 inhibitors, a common treatment strategy. This resistance mechanism was identified through a comprehensive ORF kinome screen, highlighting the potential for FGFR inhibitors to restore sensitivity to these treatments.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy